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Results: Mean age at presentation was 51±26 and 37 patients were male. TR grade was
>3 in 92%. Main etiology was traumatic (n=37, 62%), non-iatrogenic in 19 (mostly related
to motor vehicle accident) and iatrogenic in 18 (mostly related to right ventricular biopsy).
Clinical presentation was often severe: 57% were in NYHA class >II, 33% had a history
of congestive heart failure (CHF) and 40% of atrial fibrillation (AF). Compared to
expected survival of US matched population, an excess mortality was observed even
after exclusion of 11 patients in whom associated diseases could have affected the sur-
vival (3.8% yearly, p=0.02). Patients asymptomatic at presentation also experienced a
high incidence of TR-related complications (symptoms or CHF, AF, surgery or death,
75±15% at 10 years) predicted by severe enlargement of right-sided chambers (at 5
years 86±9 vs. 39±11%, p<0.01). Natural history started from date of occurrence of the
flail also showed high complication rates (69±9% at 15 years). Etiology of TR did not
influence the outcome. Tricuspid surgery was performed in 33 patients (55±7% at 5
years) and repair was performed in most patients (82%) with low mortality (3%). Despite
frequently refractory AF, surgery allowed symptomatic improvement in 88%.
Conclusion: TR due to FL is a serious disease associated with excess mortality and
high morbidity. Tricuspid valve repair can often be performed with low risk allowing symp-
tomatic improvement. These results suggest that surgery should be considered early in
the course of the disease before occurrence of intractable heart failure, particularly in
patients with dilatation of right-sided chambers.
1030-138 Valvular Regurgitation Predicts Cardiovascular 
Mortality and Morbidity Among American Indians: The 
Strong Heart Study
Felizen S. Agno, Marcello Chinali, Lyle G. Best, Jonathan N. Bella, Barbara V. Howard, 
Elisa T. Lee, Richard B. Devereux, Weill Medical College of Cornell University, New York, 
NY
Background: Valvular regurgitation has been extensively examined in cross-sectional
studies but there are few data on its association with cardiovascular (CV) morbidity and
mortality in population-based samples. Methods: In 3,199 participants (60±8 years, 64%
women, 45% hypertensive, 47% diabetic) without prevalent CV disease, valvular stenosis
or prostheses who had echocardiograms in the 2nd Strong Heart Study examination, Cox
proportional hazards models were used to estimate hazard ratios (HRs) associated with
isolated mitral regurgitation (MR) or aortic regurgitation (AR) or combined MR and AR
(MAR) for each outcome. Results: Among participants, 587 (18.3%) had MR of any
degree, 198 (6.2%) had any degree of AR and 139 (4.3%) had MAR. During 9,926 per-
son-years of follow-up, 9.0% of participants (N=289) had CV events, 12.4% (N=396) died
(28.9% of CV causes and 5.8% died suddenly). In multivariable analyses controlling for
age, gender, systolic and diastolic blood pressure, body mass index, glucose, insulin,
creatinine, lipid profile, smoking, diabetes and hypertension, MAR but not isolated MR or
AR was associated with increased risks of incident CV events (HR 2.0), CV death (HR
2.8), sudden death (HR 5.9) and all-cause death (HR 1.8)(all p<0.05, see Table for 95%
CIs). Conclusions: In a population-based sample of middle-aged and elderly adults, co-
existent MR and AR (MAR) is prevalent (4.3%) and is independently associated with
increased risk of all-cause and CV death and events. 
1030-139 Prevalence and Correlates of Mitral Regurgitation in 
Hypertensive Patients: The HyperGen Study
Zhi Bin Li, Richard B. Devereux, Jennifer E. Liu, Dalane W. Kitzman, Albert Oberman, 
Paul N. Hopkins, Charles C. Gu, Donna K. Arnett, Weill Medical College of Cornell 
University, New York City, NY
Background: The prevalence and correlates of mitral regurgitation (MR) for hypertensive
patients in a population-based sample have not been well described.
Methods: MR was accessed by color Doppler of echocardiograms in 2172 hypertensive
and 367 normotensive adults from the population-based Hypertension Genetic Epidemi-
ology Network (HyperGEN) study.
Results: Mild MR was present in 15.3%, moderate in 2.5% and severe in 1.0% of hyper-
tensive participants, versus 15.7%, 8.5% and 0.3% of normotensive adults (p=NS).
Among hypertensive patients, MR prevalence was associated with older age. After
adjusting for the effect of age, MR was associated with Caucasian ethnicity, lower body
mass index, higher systolic blood pressure, coronary artery disease, larger left atrium
size, mitral and aortic valve diseases (all p<0.05). In ANOVA and multivariate analyses
adjusted by covariates such as age, gender, body mass index, blood pressure, aortic
regurgitation, mitral valve and coronary artery disease, mild MR was associated with
increased LV mass index (95±23 vs. 87±19 g/m2) (p<0.01); moderate to severe MR were
associated with increased LV diastolic diameter (5.5±0.9 vs. 5.1±0.5 cm) and LV mass
index (105±26 vs. 87±19 g/m2), lower LV systolic function indices such as ejection frac-
tion (54±15 % vs. 62±7 %) and stress-corrected midwall shortening (99±22 % vs.
105±12 %) (all p<0.05). MR prevalence was not associated with gender, controlled or
uncontrolled hypertension, antihypertensive medication, diabetes, serum creatinine,
albumin, cholesterol and triglyceride levels (all p=NS).
Conclusions: This study showed that MR prevalence was nearly 19% among hyperten-
sive patients. It was associated with older age.After adjusting the effect from age, it was
also associated with Caucasian ethnicity, larger left atrial size, cardiovascular diseases,
systolic blood pressure difference and lower body mass index. The presence and severity
of MR were positively related to increased LV hypertrophy, greater LV dilatation and dys-
function. MR prevalence was unrelated to gender difference, diabetes, isolated hyperten-
sion and antihypertensive medication.
1030-140 Patent Foramen Ovale: A New Factor Associated With 
Progression of Carcinoid Heart Disease
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Joseph, Pascal Lacombe, Philippe Rougier, Olivier Dubourg, Hôpital Ambroise Paré, 
Boulogne, France
Background: Several studies have demonstrated that serotonin and chemotherapy were
associated with the progression of carcinoid heart disease (CHD). The aim of this pro-
spective study was to assess the role of patent foramen ovale in the progression of CHD.
Method: In 30 consecutive patients (mean age 58 years, range 40-74, 50% women) with
carcinoid syndrome, we performed serial (77) echocardiographic studies. The echocar-
diographic following parameters were systematically assessed: 1) right-CHD, 2) left-CHD,
3) right to left shunting through a patent foramen ovale (PFO) using contrast echocardio-
graphy at rest and after cough test or Valsalva maneuver.
Results: Mean follow-up was 24 months (range: 12-48 months). At baseline, echocardio-
graphy revealed 10 pts (33%) with right-CHD and 4 pts (13%) with left-CHD (Table). At
the end of follow-up, the incidence of right-CHD, left-CHD was respectively 53% (16 pts)
and 33% (10 pts). The baseline and follow-up frequencies of PFO were respectively 27%
(8 pts) and 43% (13 pts). The presence of PFO was strongly associated with the progres-
sion of both right- and left-CHD (p=0.001). The metabolite of serotonin (urinary 5-HIAA,
p=0.002) and plasmatic chromogranin A (p=0.002) levels were also predictive factors of
progression but not chemotherapy (p=0.7).Conclusion: Our data suggest that PFO is a
new important factor of carcinoid heart disease progression and should be systematically
researched by serial contrast echocardiographic studies.
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1048-136 Long-Term Results With the St. Jude Medical Aortic 
Valve: A 25-Year Experience
Robert W. Emery, Kit V. Arom, Christopher Krogh, Lyle D. Joyce, Minnesota 
Cardiovascular & Thoracic Surgeons LLC, St. Paul, MN
BACKGROUND: From 10/77 – 10/02, 2983 patients (age range 17-94 years, average
age 65 ± 13) underwent aortic valve replacement (AVR) with the St. Jude Medical (SJM)
heart valve. Concomitant coronary bypass was performed in 1239 (42%) patients.
METHODS: Cardiac Surgical Associates has maintained an independent database of
our patients having valve replacement with the SJM prosthesis since the world’s first
implant in 10/77. Patients were contacted by questionnaire and/or phone from 11/02
through 6/03. Hospital course and valve-related events were verified by patient chart
review and/or physician contact.
RESULTS: Operative mortality was 4% (AVR 3%; AVR/CAB 6% of which 15 (12% were
valve related. Total follow-up (94%) was 21,742 patient years (range 1 month to 24.8
years, average 7 ± 5 years). At 25 years, overall patient freedom from late mortality was
61% and from late valve-related mortality 93%. Freedom from thromboembolic events
was 86%; from bleeding events 81%; from endocarditis: 98%, and from valve thrombosis
99%; and from reoperation 99%. Reoperation was carried out in 51 patients (2%) for
suture closure of paravalvular leak (n=4), valve replacement (34) and debridement of
valve (13). There were no structural failures.
CONCLUSION: The SJM valve has proven to be an effective and durable heart valve
prosthesis with a low event rate over the long term.
1048-137 Impact of Valve Prosthesis-Patient Mismatch on 
Pulmonary Arterial Pressure After Mitral Valve 
Replacement
Mingzhou Li, Jean G. Dumesnil, Patrick Mathieu, Philippe Pibarot, Laval University, 
Sainte-Foy, PQ, Canada
Background: Pulmonary arterial (PA) hypertension is a serious complication of mitral
valve disease and it is a major risk factor for poor outcome following mitral valve replace-
ment (MVR). We hypothesised that valve prosthesis-patient mismatch (PPM) might be a
determinant of PA hypertension after MVR. Methods: Systolic PA pressure was mea-
sured by Doppler-echocardiography in 56 patients with normally functioning mitral pros-
thetic valves at 24±14 months after MVR. Mitral valve effective orifice area (MVA) was
determined by the continuity equation and indexed for body surface area. Results: Sev-
enty one (71) percent of patients had PPM defined as an indexed MVA < 1.2 cm2/m2.
Thirty patients (54%) had a systolic PA pressure > 40 mmHg and 13 patients (24 %) had
a systolic PA pressure > 50 mmHg. There was a good correlation (r=0.64) between sys-
tolic PA pressure and indexed MVA (see figure). The average systolic PA pressure and
prevalence of PA hypertension (PA pressure > 40 mmHg) were 34±8 mmHg and 19% in
Association of Valvular Regurgitation With Morbidity and Mortality
Events MR alone
HR (95% CI)
AR alone
HR (95% CI)
Combined MR and AR
HR (95% CI)
CV Events 1.3 (0.9 to 1.8) 1.3 (0.8 to 2.1) 2.0 (1.2 to 3.2)
CV Death 1.4 (0.8 to 2.3) 1.4 (0.7 to 2.8) 2.8 (1.4 to 5.5)
Sudden Death 2.2 (0.7 to 7.1) 1.2 (0.2 to 6.5) 5.9 (1.4 to 25.6)
All-cause Death 1.2 (0.9 to 1.6) 1.1 (0.7 to 1.6) 1.8 (1.2 to 2.8)
